When the Market Reprices What You Are Building

Boston Scientific paid $1.5 billion for 34% of MiRus on May 18 with a $3 billion milestone-gated option to acquire the rest. Stryker closed $835 million for Amplitude Vascular with roughly half in milestones. Embecta closed £150 million for Owen Mumford with a third in milestones. The CMS-FDA RAPID Coverage Pathway compressed Medicare coverage to 60 to 90 days after FDA authorization. Four signals across two weeks, all telling MedTech founders that the unit of value the buyer and payer side are pricing has shifted from the finished asset to the milestone schedule that produces it. Understanding the market is only part of the job. Making money, building systems, and getting to where you want to go — those are the problems The Build exists to help you think through, and the most useful structural question across them all is this one. What unit of value is the buyer side in your category actually pricing today, and when did the unit change?

Every Category Reprices What You Are Selling Eventually

Markets reprice. The unit of value the buyer side rewards shifts on a multi-year cadence in every industry where the technology, the regulation, the capital environment, or the customer behavior changes faster than the operating plan inside a typical first-time business updates. In SaaS, the pricing unit moved from seat to outcome and the businesses that ran the seat unit through the repricing window lost the participation profile the outcome unit reads. In consumer hardware, the pricing unit moved from device to subscription and the businesses that ran the device unit through the repricing window lost the unit economics the subscription unit produces. In MedTech in 2026, the pricing unit has moved from finished asset to milestone schedule, and the businesses running the finished-asset unit through this repricing window are losing the deal structure the milestone unit produces.

The default first-time founder reads the market repricing as a backdrop the business will run against, and treats the assumption about what the buyer is pricing as a question that gets answered once at the seed-stage operating model and then held constant. The build-phase logic is that the technical capability is the asset the buyer will pay for, that the buyer’s pricing logic is stable across the multi-year build window, and that the operating plan can be revisited at the milestones the company hits along the way. The cost shows up at the term-sheet table, the customer renewal conversation, or the capital window, when the buyer is pricing a unit of value the operating plan was not engineered to produce. The market repriced while the business was being built, and the business was not designed to absorb the repricing.

The founders who arrive at the buyer-side conversation with the unit of value the repriced market actually rewards do something different. They read the buyer-side pricing logic continuously across the build phase as a primary input into the operating plan. They identify the structural mechanisms moving the unit of value the buyer side is pricing, whether that is a deal-structure shift, a reimbursement-design shift, a customer-contract shift, or a capital-market shift. They engineer the operating plan, the architecture, and the financial model against the post-repricing unit rather than against the seed-stage unit. The four MedTech signals across May 2026 are the cleanest current public example of a market repricing in real time, and the founders running the milestone unit have already updated the operating plan against the new pricing logic.

How to Read the Repricing in Your Category

Reading the repricing in your category is a research and synthesis discipline, and it compounds through the build phase into the operating-plan resilience the repriced market requires. The founders who run the discipline well start by identifying the unit of value the buyer side has been pricing across the prior multi-year window, then track the structural mechanisms that are moving the unit. Deal structures across the most recent comparable transactions are one tracker. Reimbursement design across the relevant payer side is another. Customer contracts across the install base are a third. Capital-market positioning across the financing trajectory is a fourth. Each tracker generates a signal when the pricing unit moves, and the operating plan inside the business updates against the move on the same quarterly review rhythm.

At the operating level, the discipline produces a buyer-side pricing map that the business runs the architectural, financial, and operating decisions against. The map identifies the specific unit of value the buyer side is currently rewarding, the structural mechanisms that are moving the unit, the operating-plan assumptions that have to update against the move, and the participation profile the repriced market now reads. The companies that finish in a repriced market do the architectural and operating work that compounds through the build phase into the participation profile the new unit reads, with the financial model, the deal architecture, and the operating cadence all updated quarterly against the most recent buyer-side signal. The companies that stall treat the repricing as a backdrop and discover the new unit at the moment the operating plan needs the old unit to be true.

Building the Operating System That Catches the Repricing

The operating system inside a business that catches the repricing is built around three durable functions. The first is the buyer-side tracking review that runs alongside the engineering, regulatory, and commercial cadence with the same operating intensity. The review covers the most recent comparable deal structures, the reimbursement design shifts the payer side is producing, the customer-contract patterns inside the install base, the capital-market positioning around the financing trajectory, and the structural shifts that are moving the pricing unit the buyer side rewards. The second is the architecture and operating-plan update cadence that runs the financial, deal, and operating decisions on a quarterly review rhythm, with the operating-plan assumptions updated against the most recent repricing signal. The third is the operating discipline that resources the tracking and the update work as a Day-1 capital line equivalent in scale to the visible product work that produces the next visible milestone.

Founders who build this operating system arrive at each buyer-side conversation with the unit of value the repriced market actually rewards. Founders who defer it arrive with the unit the market priced two years earlier, and the cost shows up at the conversation that should have been the win. The compounding effect of building the tracking and update system through the build phase is one of the most asymmetric returns the founder operating plan can generate, and one of the most expensive operating compromises to skip when the architectural work is competing for time and capital with the visible product engineering. The Build covers the structural and operating questions that produce the post-repricing participation profile in practical terms for founders running real businesses across industries. What unit of value is the buyer side in your category pricing right now? Which structural mechanisms are about to move the unit again? Which operating-plan assumptions are sitting on the prior pricing logic? Which architectural work has to update before the next buyer-side conversation arrives?

What the Four MedTech Signals This Week Show in Practice

The Boston Scientific stake in MiRus is the public-facing signal that the strategic acquirer side of MedTech is gating 30 to 50 percent of headline deal value behind clinical and regulatory milestones the term sheet enumerates, against a prior pricing logic that paid the headline number for a finished asset. The Stryker close on Amplitude Vascular and the Embecta close on Owen Mumford confirm that the milestone-gated structure is the operating posture across the buyer side, not a one-off term applied to an unusual asset. The HistoSonics De Novo submission for kidney tumors shows that platform companies are sequencing indications as the unit of value across multiple readouts, with each indication a fundable milestone the operating plan stages against. The RAPID Coverage Pathway compresses the reimbursement timeline to a single FDA-CMS milestone window, with the payer side pricing the same milestones the acquirer side is pricing. Read together, the four signals describe a market repricing the unit of value from finished asset to milestone schedule in real time. The MedTech founders running the milestone unit are operating against the repriced market. The MedTech founders running the finished-asset unit are running a business the market just moved past, and the cost will show up at the next term-sheet table, the next capital window, or the next reimbursement event.